Comparison of the coagulopathies associated with COVID-19 and sepsis.
Robert A CampbellYohei HisadaFrederik DenormeSteven Philip GroverEmma G BouckElizabeth A MiddletonAlisa S WolbergMatthew T RondinaNigel MackmanPublished in: Research and practice in thrombosis and haemostasis (2021)
High levels of both EVTF activity and active PAI-1 may promote thrombosis in patients with COVID-19 due to simultaneous activation of coagulation and inhibition of fibrinolysis. The high levels of active PAI-1 in patients with COVID-19 may limit plasmin degradation of crosslinked fibrin and the release of d-dimer. This may explain the lower levels of D-dimer in patients with COVID-19 compared with patients with sepsis.